Aimeee Ennis

This accomplished biopharmaceutical leader brings more than two decades of progressive experience in the healthcare and life sciences industry, with extensive expertise spanning neurology, population health, commercial leadership, stakeholder engagement, and healthcare ecosystem strategy. Throughout a distinguished career with UCB, she has consistently advanced through increasingly influential leadership roles, demonstrating a strong ability to build strategic partnerships and drive meaningful healthcare outcomes.

Currently serving as a Thought Leader Liaison, she collaborates with key opinion leaders, healthcare experts, and clinical stakeholders to advance scientific exchange, strengthen professional relationships, and support the adoption of innovative therapies. Prior to this role, she served as U.S. Neurology Ecosystem Lead for Texas, where she developed and executed strategic initiatives designed to improve patient access, care coordination, and health system engagement across complex neurological disease states.

Her earlier leadership roles include Population Health Partner, District Manager, CNS Executive Sales Specialist, and Professional Sales Representative, providing her with a comprehensive understanding of healthcare delivery, commercial strategy, provider engagement, and patient-centered care. Across these positions, she successfully partnered with physicians, health systems, and multidisciplinary healthcare teams to support improved clinical outcomes and strengthen organizational performance.

Known for her ability to bridge clinical, operational, and strategic priorities, she has built a reputation as a collaborative leader who excels at navigating complex healthcare environments, fostering stakeholder alignment, and delivering value across the healthcare ecosystem. Her career reflects a deep commitment to advancing patient care, supporting healthcare innovation, and cultivating meaningful partnerships that drive sustainable impact.

With more than 24 years of industry experience, she continues to be a trusted leader in the biopharmaceutical sector, leveraging her expertise in neurology, population health, strategic engagement, and healthcare transformation to help shape the future of patient care.